RxDoctor Payments Data

Roger Tolar, MD

Family Medicine · Keller, TXNPI 1255365276

Payments from drug & device makers

$17,041in general payments, 2019–2025

Across 808 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$983
  • Boehringer Ingelheim$637
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1,2007%
  • Travel & lodging$3492%
  • Food & beverage$15,48391%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$2,100
Biohaven Pharmaceutical Holding Company Ltd.15$1,891
AstraZeneca44$1,276
Novo Nordisk91$1,271
Pfizer54$983
Boehringer Ingelheim38$637
Lilly USA, LLC42$628
GSK25$576
Amarin Pharma, Inc.21$520
Merck31$489
Antares Pharma, Inc.29$471
Tris Pharma Inc20$432
Johnson & Johnson20$420
Amgen21$413
Takeda Pharmaceuticals U.S.A., Inc.25$379
Bayer15$351
Corcept Therapeutics11$340
Biohaven Pharmaceuticals, Inc.9$303
Astellas Pharma US Inc13$265
Supernus Pharmaceuticals, Inc.12$236
Genentech USA, Inc.9$215
Ironshore Pharmaceuticals Inc.13$212
Idorsia Pharmaceuticals US Inc7$200
Abbott9$198
Phathom Pharmaceuticals, Inc.6$196
Eisai Inc.10$179
Halozyme Inc7$156
Corium, LLC6$148
Verity Pharmaceuticals Inc.7$127
Esperion Therapeutics, Inc.8$127
Medtronic3$111
Teva Pharmaceuticals USA, Inc.7$95
Tolmar, Inc.5$87
Exact Sciences4$79
Novartis5$74
Collegium Pharmaceutical, Inc.4$62
Azurity Pharmaceuticals, Inc.4$61
Dexcom, Inc.3$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$52
Pacira Therapeutics, Inc.3$48
Clarus Therapeutics Inc.4$47
Neos Therapeutics, LP3$46
Inspire Medical Systems, Inc.2$36
Xeris Pharmaceuticals, Inc.2$36
Shire North American Group Inc2$34
Adlon Therapeutics L.p.2$33
Dynavax Technologies Corporation2$31
Acerus Pharmaceuticals Corporation2$30
Bausch Health US, LLC2$25
Kowa Pharmaceuticals America, Inc.2$25
Arbor Pharmaceuticals, Inc.2$25
Lundbeck LLC2$24
Sanofi-aventis U.S. LLC2$23
IBSA Pharma Inc.1$21
Bioventus LLC1$20
Jazz Pharmaceuticals Inc.1$20
Otsuka America Pharmaceutical, Inc.1$20
Kaleo, Inc.1$18
Aytu Biopharma, Inc.1$15
Daiichi Sankyo Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,041 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$86,341
Medicare patients
215
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$123,591
MounjaroTirzepatide58$81,346
EliquisApixaban68$67,732
TrulicityDulaglutide40$62,316
Repatha SureclickEvolocumab50$48,647
OzempicSemaglutide28$47,206
Synjardy XrEmpagliflozin/Metformin Hcl33$37,615
FarxigaDapagliflozin Propanediol12$14,588
MyrbetriqMirabegron11$14,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,222
Rosuvastatin Calcium524$5,403
Levothyroxine Sodium348$3,360
PaxlovidNirmatrelvir/Ritonavir13$2,858
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,637
Ezetimibe155$2,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$637$161,206131 claims
Lilly USA, LLCMounjaro, Trulicity$628$143,66298 claims
PfizerEliquis, Paxlovid$983$70,59181 claims
Novo NordiskOzempic$1,271$47,20628 claims
AstraZenecaFarxiga$1,276$14,58812 claims
Astellas Pharma US IncMyrbetriq$265$14,34511 claims
GSKTrelegy Ellipta$576$11,22213 claims
AbbVieSynthroid$2,100$2,36344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Keller

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →